Hidradenitis suppurativa specialists are focusing new attention on how clinicians can optimize the use of biologics, combination therapy, and surgery — the three pillars of management for a disease that still challenges even experienced dermatologists.

A recently published expert discussion from HCPLive, titled "Tips on Optimizing HS Biologics, Combinations, and Surgery," centers on practical decision-making for a chronic inflammatory condition that affects the intertriginous skin and frequently progresses to irreversible structural damage when treatment is delayed or fragmented.

What makes HS treatment sequencing difficult?

HS does not follow a uniform course. Patients present across a wide spectrum — from intermittent inflammatory nodules and abscesses to tunneling, fibrosis, and fixed scar tracts that no longer respond to anti-inflammatory therapy alone. That heterogeneity forces clinicians to decide, at each visit, whether the patient in front of them needs medical escalation, surgical intervention, or both.

The expert conversation addresses exactly this junction point. The core question is not whether biologics work in HS, but when to start them, when to layer additional agents on top, and when to conclude that medical therapy alone has reached its limit and structural disease requires operative management.

How should biologics be optimized?

For inflammatory disease, biologic therapy has become central to modern HS management, and the discussion emphasizes getting the most from these agents rather than simply prescribing them. Optimization, in this framing, covers several practical dimensions:

• Confirming that the patient's disease burden and trajectory justify biologic initiation
• Setting realistic expectations about response timelines before the first injection
• Monitoring response systematically rather than relying on impression
• Deciding when an inadequate response calls for dose adjustment, switching, or combination

The experts frame combination therapy as a legitimate strategy rather than a rescue afterthought. In a disease where both inflammation and pain contribute to disability, pairing a biologic with adjunctive systemic agents can address components of the disease that a single mechanism leaves untouched.

When does surgery enter the picture?

The surgical discussion confronts a persistent point of clinical tension: operating too early exposes patients to procedures they did not need, while operating too late leaves fixed tunnels and fibrosis that compromise outcomes. The guidance aims to help clinicians recognize the transition point where inflammatory disease gives way to structural disease.

Crucially, the two treatment pillars are not mutually exclusive. Surgical intervention and ongoing biologic therapy can coexist in the same treatment plan, with medical therapy controlling active inflammation around the time of operative management and reducing the risk of postoperative flares.

Why does this discussion matter now?

HS remains underdiagnosed and undertreated, with years of diagnostic delay common in real-world practice. Patients frequently cycle through antibiotics and short courses of prednisone before reaching a clinician who recognizes the disease pattern and initiates appropriate therapy.

Expert discussions of this kind matter because they translate trial data into chairside decisions — the specific judgments about escalation, combination, and surgical referral that guidelines often leave to individual interpretation. For a disease with limited approved options relative to conditions such as psoriasis, squeezing full value from each available therapy is a clinical imperative.

What should clinicians take away?

The central message is that HS management succeeds when clinicians treat it as a dynamic, multimodal problem rather than a stepwise algorithm. Biologics, combination regimens, and surgery each address a different face of the disease, and sequencing them well requires deliberate reassessment over time.

As biologic options in HS continue to expand and real-world experience with combination and surgical strategies accumulates, discussions like this one are likely to shape how dermatology practices structure care pathways for one of the field's most demanding chronic inflammatory diseases.